Decheng Capital LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002010850

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2025 · 25 positions · Total reported value $395.97M · Top-10 concentration 92.4% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 35.7% · 0 new · 2 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -3.5% · vs SPY -5.6% · Prev Value $731.75M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -13.4% · vs SPY -15.6% · Latest Value $685.07M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2025 13F filing, Decheng Capital LLC disclosed 25 equity positions with a combined reported value of $395.97M. The filing implies a focused portfolio: its ten largest positions account for 92.4% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were CGON ($165.66M), AARD ($52.96M), NUVB ($50.61M). By sector, the heaviest allocations are Health Care 93.1%, Other 6.9%.

Versus the prior quarter, Decheng Capital LLC opened 0 new positions, trimmed 2 and fully exited 3, a turnover rate of 35.7% of positions. The portfolio's overlap with the prior quarter was 86% of names.

The largest new positions opened in Q2 2025 were RZLT ($267.15K).

Of the 3 positions fully exited versus the prior quarter, the largest were CYTK ($4.02M), BNTX ($1.82M), VERA ($107.97K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • RZLT REZOLUTE INC COM NEW · $267.15K

Fully Exited (vs previous quarter)

  • CYTK CYTOKINETICS INC · prev qtr: $4.02M
  • BNTX BIONTECH SE · prev qtr: $1.82M
  • VERA VERA THERAPEUTICS INC · prev qtr: $107.97K

Insider Transactions (Form 4)

Latest Decheng Capital LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Decheng Capital LLC, based in Menlo Park, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 14 positions worth $731.75M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: MENLO PARK, CA, United States
  • SEC registration: 801-118587 (status: Approved), registered 2020-04-30
  • Regulatory AUM (Form ADV): $2.73B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 8 private funds, of which 1 hedge funds
  • Website: decheng.com

Portfolio Structure

  • 14 positions · $731.75M reported value (Q2 2026)
  • Top 10 holdings = 98.1% of reported value
  • Largest position: CGON (CG ONCOLOGY INC) at 61.9%
  • Average position size: $52.27M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 3 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 93.1%
Other 6.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 6.37M $165.66M 41.84%
41.84%
Hold
2 3.92M $52.96M 13.38%
13.38%
Hold
3 25.95M $50.61M 12.78%
12.78%
Hold
4 3.29M $36.07M 9.11%
9.11%
Hold
5 770.00K $13.94M 3.52%
3.52%
Hold
6 4.53M $10.65M 2.69%
2.69%
Reduce
7 189.10K $9.95M 2.51%
2.51%
Hold
8 66.00K $9.07M 2.29%
2.29%
Add
9 181.60K $8.57M 2.17%
2.17%
Add
10 226.00K $8.31M 2.10%
2.10%
Hold
11 4.04M $5.74M 1.45%
1.45%
Hold
12 595.47K $5.26M 1.33%
1.33%
Reduce
13 547.61K $4.46M 1.13%
1.13%
Add
14 143.00K $4.11M 1.04%
1.04%
Reduce
15 515.55K $3.23M 0.81%
0.81%
Hold
16 1.32M $1.54M 0.39%
0.39%
Reduce
17 4.45M $1.40M 0.35%
0.35%
Hold
18 239.51K $888.58K 0.22%
0.22%
Reduce
19 160.00K $811.20K 0.20%
0.20%
Reduce
20 7.98K $761.28K 0.19%
0.19%
Reduce
21 20.00K $709.80K 0.18%
0.18%
Reduce
22 9.68K $497.95K 0.13%
0.13%
Hold
23 326.81K $359.49K 0.09%
0.09%
Hold
24 59.90K $267.15K 0.07%
0.07%
New
25 646.06K $127.35K 0.03%
0.03%
Hold

FAQ

What did Decheng Capital LLC buy in 2025-Q2?

In its 2025-Q2 13F filing, Decheng Capital LLC reported 25 equity positions worth $395.97M in aggregate; its largest disclosed positions were CGON ($165.66M), AARD ($52.96M), NUVB ($50.61M).

How large is Decheng Capital LLC's portfolio?

Decheng Capital LLC reported $395.97M of long equity holdings across 25 positions as of 2025-Q2. Top-10 holdings account for 92.4% of reported value.

What is Decheng Capital LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/decheng-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →